HeartMate 3 LVAD Neurologic Events Beyond Stroke Carry High Mortality Risk
A retrospective registry analysis of nearly 12,000 patients with advanced heart failure who received the HeartMate 3 LVAD found that stroke and nonstroke neurologic adverse events each occurred in about 8% over a median 1.4 years. Both types of events were tied to lower survival, with the highest mortality risk seen after overt central nervous system injury. The researchers identified pre-implant ECMO use and concurrent surgery as possible modifiable factors for reducing neurologic complications.
The analysis drew on the U.S. INTERMACS registry, covering roughly 12,000 advanced heart failure patients implanted with the HeartMate 3 magnetically levitated pump, followed a median 1.4 years. Stroke and nonstroke neurologic adverse events each appeared in about 8%. Two-year survival was 45% after stroke and 56% after nonstroke events.
Death risk climbed most with obvious central nervous system damage (HR 12.58), followed by imaging-detected covert injury (HR 9.19) and dysfunction without CNS injury such as encephalopathy (HR 3.69). Outside experts noted the nonstroke category mixes clinically diverse conditions, and that encephalopathy may signal infection, shock, or multiorgan failure rather than cause death directly.
Roughly 12,000 registry patients inform this, but the implications could reach the broader advanced heart failure population weighing LVAD therapy. Patients and families may face harder conversations about neurologic risk beyond stroke, while clinicians could reconsider pre-implant ECMO use and concurrent surgery as targets. Because the nonstroke category is heterogeneous, its findings may complicate how device safety is communicated and compared, potentially affecting regulatory and institutional discussions about how neurologic outcomes are named and tracked.